Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Recruiting

This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and romidepsin may work better than pembrolizumab alone in treating participants with recurrent or refractory peripheral T-cell lymphoma.

Study Type:    Interventional

Study Design:    

Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title:    A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma   

Conditions:  

Recurrent Anaplastic Large Cell Lymphoma
Recurrent Angioimmunoblastic T-Cell Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Anaplastic Large Cell Lymphoma
Refractory Angioimmunoblastic T-Cell LymphomaRefractory Angioimmunoblastic T-Cell Lymphoma
Refractory Mycosis Fungoides
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
 

Intervention:  Biological: Pembrolizumab

                       Drug:  Romidepsin      

Phase:  Phase 1/2

External Link:  https://clinicaltrials.gov/ct2/show/NCT03278782